These findings indicate that the attenuation of the glycolytic phenotype induced by B-raf inhibition is mediated—at least in part—by the transcription factor Hif-1α, which controls the expression of a network of genes involved in energy metabolism and specifically altered in BRAF-like tumour samples. Here, HIF1A is linked to neoplasm.